Literature DB >> 8409426

Construction of a human Ig combinatorial library from genomic V segments and synthetic CDR3 fragments.

Y Akamatsu1, M S Cole, J Y Tso, N Tsurushita.   

Abstract

A naive combinatorial Ig library was constructed from semi-synthetic V genes consisting of human genomic V segments and synthetic CDR3 fragments. VH and V kappa segments were amplified from human genomic DNA by polymerase chain reaction using V subgroup-specific primers. The amplified VH and V kappa segments were combined with synthetic oligonucleotides containing a J region and CDR3 with amino acid sequence variations, resulting in complete V genes. These V genes were cloned into a phagemid expression vector in a single-chain form fused to the carboxyl-terminus of the M13 minor coat protein III. Phagemid particles displaying the single chain hybrid proteins on their surface were screened with Con A as Ag. Several clones showing specific binding to Con A were obtained after four rounds of selection and were further analyzed for their binding properties and DNA sequences. This method provides a novel way to create a naive combinatorial library without using mRNA from B lymphocytes as template. The method should be useful to isolate human antibodies that react with self-Ag.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8409426

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  Construction of a semisynthetic antibody library using trinucleotide oligos.

Authors:  M Braunagel; M Little
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

Review 3.  Infectious disease antibodies for biomedical applications: A mini review of immune antibody phage library repertoire.

Authors:  Jing Yi Lai; Theam Soon Lim
Journal:  Int J Biol Macromol       Date:  2020-07-08       Impact factor: 6.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.